Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ECOR 
Electrocore LLC (ECOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ECOR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $21.4
1 Year Target Price $21.4
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 16.71% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 36.70M USD | Price to earnings Ratio - | 1Y Target Price 21.4 |
Price to earnings Ratio - | 1Y Target Price 21.4 | ||
Volume (30-day avg) 5 | Beta 0.36 | 52 Weeks Range 4.16 - 19.49 | Updated Date 09/16/2025 |
52 Weeks Range 4.16 - 19.49 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.6 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -47.84% | Operating Margin (TTM) -47.5% |
Management Effectiveness
Return on Assets (TTM) -44.19% | Return on Equity (TTM) -210.58% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33716039 | Price to Sales(TTM) 1.32 |
Enterprise Value 33716039 | Price to Sales(TTM) 1.32 | ||
Enterprise Value to Revenue 1.22 | Enterprise Value to EBITDA 0.16 | Shares Outstanding 7583440 | Shares Floating 5364301 |
Shares Outstanding 7583440 | Shares Floating 5364301 | ||
Percent Insiders 37.28 | Percent Institutions 15.5 |
Upturn AI SWOT
Electrocore LLC
Company Overview
History and Background
Electrocore LLC is a commercial-stage bioelectronic medicine company focused on developing non-invasive vagus nerve stimulation (nVNS) therapy. Founded in 2005, it has focused on neuromodulation devices as an alternative to medication for various conditions. Key milestones include FDA clearances for gammaCore devices and commercialization efforts.
Core Business Areas
- Neuromodulation Devices: Development, manufacturing, and commercialization of non-invasive vagus nerve stimulation (nVNS) devices for the treatment of migraine, cluster headache, and other conditions.
Leadership and Structure
The leadership team includes the CEO, CFO, and other key executives. The company operates with a functional organizational structure with dedicated teams for R&D, manufacturing, commercialization, and regulatory affairs.
Top Products and Market Share
Key Offerings
- gammaCore Sapphire nVNS: A non-invasive vagus nerve stimulation device FDA-cleared for acute treatment of migraine and cluster headache in adults, as well as adjunctive therapy for PTSD. Market share data is challenging to acquire and is not publicly available due to the specialized nature of the market. Competitors include other neuromodulation and pharmaceutical companies.
Market Dynamics
Industry Overview
The neuromodulation industry is growing, driven by increasing demand for non-pharmacological treatment options and technological advancements. The vagus nerve stimulation segment is a key area within neuromodulation.
Positioning
Electrocore LLC is positioned as a pioneer in non-invasive vagus nerve stimulation, offering a novel therapy for headache and other conditions. Its competitive advantages include its patented technology and FDA clearances.
Total Addressable Market (TAM)
The global neuromodulation market is estimated at billions of dollars. Electrocore aims to capture a share of this market by expanding the indications for gammaCore and expanding internationally. Exact TAM data is not publicly available.
Upturn SWOT Analysis
Strengths
- FDA cleared device
- Patented technology
- First mover advantage in nVNS for certain indications
- Established relationships with healthcare providers
Weaknesses
- Limited clinical data compared to established treatments
- Dependence on insurance reimbursement
- Relatively small commercial footprint
- Cash burn
Opportunities
- Expanding indications for gammaCore
- International expansion
- Partnerships with pharmaceutical companies
- Increased awareness of neuromodulation as a treatment option
Threats
- Competition from established headache treatments
- Regulatory changes
- Reimbursement challenges
- Potential for adverse events
Competitors and Market Share
Key Competitors
- CRMD
- BSX
- STIM
Competitive Landscape
Electrocore has a specific advantage in nVNS devices, but faces larger, established companies with broader neuromodulation portfolios. Their success depends on expanding their clinical evidence base, securing favorable reimbursement, and expanding their commercial reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are unavailable without access to non-public financial data.
Future Projections: Future projections are unavailable without access to non-public financial data.
Recent Initiatives: Recent initiatives include ongoing clinical trials, product development efforts, and commercialization activities.
Summary
Electrocore LLC is a pioneering company in the field of non-invasive vagus nerve stimulation with FDA-cleared devices for headache. Its patented technology provides a competitive advantage, but the company faces challenges related to reimbursement, commercial scale, and competition from larger companies. Expanding indications and geographic reach are essential for future growth. Without substantial revenue growth Electrocore is at risk of being taken over, or going bankrupt due to its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- FDA filings
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share estimates are approximate and based on industry analysis. Electrocore is a private company, so information may be limited.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Electrocore LLC
Exchange NASDAQ | Headquaters Rockaway, NJ, United States | ||
IPO Launch date 2018-06-22 | CEO & Director Mr. Daniel S. Goldberger | ||
Sector Healthcare | Industry Medical Devices | Full time employees 73 | Website https://www.electrocore.com |
Full time employees 73 | Website https://www.electrocore.com | ||
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation ("nVNS") technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.